Epineuron announces launch of FDA clinical trial for bioelectronic therapy for nerve regeneration

OBIO NewsOntario Industry Updates
Written By Arsheen Kaur

Epineuron recently announced the official launch of an FDA clinical trial for PeriPulse™, breakthrough solution for bioelectronic nerve regeneration therapy. Building on robust research led by its scientific and clinical advisory board, the company has successfully obtained regulatory approval to conduct a multicentre clinical trial in traumatic acute nerve injury for this breakthrough therapy.

Epineuron is an alumnus of the BDSP™, CAAP®, HealthMINT™, H2BB™, and WiHI programs, and presented at the OBIO® Investment Summit.

Arsheen Kaur
Previous

VBI Vaccines and Brii Biosciences expand Hepatitis B partnership to address prevention and treatment

Next

Recursion announces collaboration and $50 million investment from NVIDIA